Lesson plan

MK-4541

MK-4541 is a dual selective androgen receptor modulator (SARM) and 5α-reductase inhibitor (5α-RI) which has been of interest for the potential treatment of prostate cancer but has not been marketed at this time. It is intended for use by mouth. The drug is a steroidal androgen receptor (AR) modulator with mixed agonistic (androgenic) and antagonistic (antiandrogenic) effects. In preclinical research and animal studies, MK-4541 has been found to have androgenic or anabolic effects in muscle and bone, to strongly suppress testosterone levels (likely via androgenic antigonadotropic effects), and to have antiandrogenic effects in the prostate and in prostate cancer cells. Structurally, it is specifically a 4-azasteroid derivative. MK-4541 was first described in the scientific literature by 2014. It was identified by screening of 3,000 compounds that were manually designed and predicted to have SARM activity. The drug was developed by Merck. It might be being developed for potential medical use, but its developmental status has not been publicly disclosed. In any case, MK-4541 is not known to have advanced past preclinical studies as of 2020.

Back to article

Article summary

MK-4541 is a dual selective androgen receptor modulator (SARM) and 5α-reductase inhibitor (5α-RI) which has been of interest for the potential treatment of prostate cancer but has not been marketed at this time. It is intended for use by mouth. The drug is a steroidal androgen receptor (AR) modulator with mixed agonistic (androgenic) and antagonistic (antiandrogenic) effects. In preclinical research and animal studies, MK-4541 has been found to have androgenic or anabolic effects in muscle and bone, to strongly suppress testosterone levels (likely via androgenic antigonadotropic effects), and to have antiandrogenic effects in the prostate and in prostate cancer cells. Structurally, it is specifically a 4-azasteroid derivative. MK-4541 was first described in the scientific literature by 2014. It was identified by screening of 3,000 compounds that were manually designed and predicted to have SARM activity. The drug was developed by Merck. It might be being developed for potential medical use, but its developmental status has not been publicly disclosed. In any case, MK-4541 is not known to have advanced past preclinical studies as of 2020.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.